Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cosimo Bruni

Showing results (141-150 of 166) with videos related to

Pageof 17
Sort By:
Annals of the Rheumatic Diseases|February 2, 2025
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR databaseQingran Yan, Cosimo Bruni, Alexandru Garaiman, et al.
Diagnostics (Basel, Switzerland)|February 10, 2024
The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research DatabaseGemma Lepri, Cosimo Bruni, Lorenzo Tofani, et al.
Rheumatology (Oxford, England)|January 8, 2025
Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohortEliane Roth, Cosimo Bruni, Liubov Petelytska, et al.
The Lancet. Rheumatology|May 17, 2025
Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort studyAnna-Maria Hoffmann-Vold, Liubov Petelytska, Håvard Fretheim, et al.
Rheumatology (Oxford, England)|February 27, 2026
Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvementLaura Ross, Andrew T Burns, André La Gerche, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomesGemma Lepri, Paolo Airò, Oliver Distler, et al.
Rheumatology (Oxford, England)|January 29, 2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysisHilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
Annals of the Rheumatic Diseases|January 18, 2026
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)Liubov Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, et al.
The Lancet. Rheumatology|January 24, 2024
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statementsAnna-Maria Hoffmann-Vold, Toby M Maher, Edward E Philpot, et al.
Pageof 17

Showing results (141-150 of 166) with videos related to

Sort By:
Pageof 17
Annals of the Rheumatic Diseases|February 2, 2025
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR databaseQingran Yan, Cosimo Bruni, Alexandru Garaiman, et al.
Diagnostics (Basel, Switzerland)|February 10, 2024
The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research DatabaseGemma Lepri, Cosimo Bruni, Lorenzo Tofani, et al.
Rheumatology (Oxford, England)|January 8, 2025
Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohortEliane Roth, Cosimo Bruni, Liubov Petelytska, et al.
The Lancet. Rheumatology|May 17, 2025
Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort studyAnna-Maria Hoffmann-Vold, Liubov Petelytska, Håvard Fretheim, et al.
Rheumatology (Oxford, England)|February 27, 2026
Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvementLaura Ross, Andrew T Burns, André La Gerche, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomesGemma Lepri, Paolo Airò, Oliver Distler, et al.
Rheumatology (Oxford, England)|January 29, 2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysisHilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
Annals of the Rheumatic Diseases|January 18, 2026
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)Liubov Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, et al.
The Lancet. Rheumatology|January 24, 2024
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statementsAnna-Maria Hoffmann-Vold, Toby M Maher, Edward E Philpot, et al.
Pageof 17